Avidity Partners Management’s Orchestra BioMed OBIO Stock Holding History

Avidity Partners Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400,000	Closed	-$3.99M	–	91
2022 Q4	$3.99M	Hold	400,000	–	–	0.09%	71
2022 Q3	$3.96M	Hold	400,000	–	–	0.08%	83
2022 Q2	$3.98M	Hold	400,000	–	–	0.09%	65
2022 Q1	$3.96M	Hold	400,000	–	–	0.08%	78
2021 Q4	$4.03M	Hold	400,000	–	–	0.09%	84
2021 Q3	$3.96M	Hold	400,000	–	–	0.09%	90
2021 Q2	$4.08M	Hold	400,000	–	–	0.11%	99
2021 Q1	$4.48M	Hold	400,000	–	–	0.12%	85
2020 Q4	$5.12M	Hold	400,000	–	–	0.17%	79
2020 Q3	$4.4M	Buy	+400,000	New	+$4.49M	0.2%	59

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SFG

SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Avidity Partners Management's OBIO Position: Q1 2023 in Review

Avidity Partners Management sold out of Orchestra BioMed (OBIO) in Q1 2023, closing a stake of 400,000 shares — an estimated $3.99M sold.

Avidity Partners Management first reported a position in OBIO in Q3 2020 and held it in 10 quarters. The position peaked at $5.12M in Q4 2020. 22 funds tracked by Wall St. Rank hold OBIO as of Q1 2023.

Avidity Partners Management reported no remaining Orchestra BioMed position as of Q1 2023 after selling out during the quarter.
Avidity Partners Management sold 400,000 Orchestra BioMed shares in Q1 2023, an estimated $3.99M.
Avidity Partners Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 10 quarters.
Avidity Partners Management's Orchestra BioMed position peaked at $5.12M in Q4 2020.
22 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2023.

Based on Avidity Partners Management's 13F filing for Q1 2023, filed 15 May 2023.